NCT06297226

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Name: Clinical Trial NCT06297226
Creator: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Keywords: Multiple Myeloma, BMS-986393, Phase 2, biological, clinical trial, Canada,United States of America

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·ClinicalTrials.gov·biologicalRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Multiple Myeloma
Drug/Device/Intervention: BMS-986393
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Location: Birmingham,Gilbert,Little Rock,Los Angeles,San Francisco,Denver,Miami,Tampa,Atlanta,Atlanta,Chicago,Chicago,Iowa City,Westwood,Saint Matthews,Boston,Boston,Rochester,Saint Louis,New Brunswick,Buffalo,, Canada,United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Mar 21, 2024
End date: Jun 04, 2030
Enrollment: 150 participants

Primary outcome

Best overall response (BOR)

Summary

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

ICD-10 classifications

Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06297226
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06297226 through Pure Global AI's free database. This Phase 2 trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and is currently Recruiting. The study focuses on Multiple Myeloma. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.